Research

Energy balance

SGLT2 inhibitors produce modest weight loss (2-5 kg) in Type 2 Diabetes, which is significantly less than the ~10 kg/year predicted by caloric loss from glycosuria due to compensatory metabolic adaptations.

If you are taking an SGLT2 inhibitor for diabetes, expect a modest weight loss of 2-5 kg, not the dramatic loss you might calculate from urine sugar loss. This modest loss is still beneficial for your heart and kidneys. Use this weight change as a motivational anchor to support other healthy lifestyle changes, rather than relying on the drug alone for significant fat loss.

GoodQualifiesHIGH confidence
The actual loss in body weight is much less, as shown in clinical trials and in clinical practice... Clinical trials and observational data show that weight reduction is lower than expected (approximately 2–5 kg)... The relationship between SGLT2 inhibition and the caloric effect turned out to be much more complex and not a simple linear function, as initially thought.
Andrej Janež et al. · Diabetes Therapy · 2021

Why this rating

Based on multiple large Cardiovascular Outcome Trials (CVOTs) and meta-analyses cited.

Source

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review

Andrej Janež et al. · Diabetes Therapy · 2021

DOI 10.1007/s13300-021-01104-z

narrative_reviewCited 52×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →